Adverse Event: Clinical Trials

3 trials for Adverse Event, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 unknown, 1 not yet recruiting. 3 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 33Unknown 2, Not yet recruiting 1
Phase 21Unknown 1

Follow Adverse Event: new trials by email Literature Review of Adverse Event trials Research Report on Adverse Event

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
18F-2-fluoro-2-deoxy-D-glucose in Positron Emission Tomography Computed Tomography
18F-2-fluoro-2-deoxy-D-glucose - Solitary Pulmonary Nodule, Oncology
Phase 3Not yet recruitingEastern Health, Canada100002020-11-012020-11-04
Long-acting G-CSF for Febrile Neutropenia
long-acting granulocyte colony stimulating factor, Short-term granulocyte colony stimulating factor - Epithelial Ovarian Cancer, Colony Stimulating Factors
Phase 3UnknownLei Li5562018-11-102018-11-14
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
Akynzeo, Dexamethasone - Chemotherapy-induced Nausea and Vomiting, Adverse Event
Phase 2 / Phase 3UnknownChristina Ruhlmann802018-09-052021-12-14

Narrower conditions

Carcinoma, Ovarian Epithelial (1)  ·  Febrile Neutropenia (1)  ·  Neoplasms (1)  ·  Solitary Pulmonary Nodule (1)  ·  Uterine Cervical Neoplasms (1)  ·  Vomiting (1)

Broader conditions

Female Urogenital Diseases (2)  ·  Female Urogenital Diseases and Pregnancy Complications (2)  ·  Genital Diseases (2)  ·  Genital Diseases, Female (2)  ·  Genital Neoplasms, Female (2)  ·  Neoplasms (2)  ·  Neoplasms by Site (2)  ·  Urogenital Diseases (2)  ·  Urogenital Neoplasms (2)  ·  Adnexal Diseases (1)  ·  Agranulocytosis (1)  ·  Carcinoma (1)  ·  Cytopenia (1)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)

Interventions

Dexamethasone (1)  ·  netupitant, palosentron drug combination (1)

Sponsors

Christina Ruhlmann (1)  ·  Eastern Health, Canada (1)  ·  Lei Li (1)

Countries

China (1)  ·  Denmark (1)

Top investigators

Christina H. Ruhlmann, MD, PhD (1)  ·  Lei Li, M.D. (1)

Results publications

PMID 31467066, PMID 40437122